U. Theuretzbacher, F. Ihle, and H. Derendorf, Pharmacokinetic/Pharmacodynamic Profile of Voriconazole, Clinical Pharmacokinetics, vol.26, issue.7, pp.649-663, 2006.
DOI : 10.2165/00003088-200645070-00002

D. Mitsani, M. H. Nguyen, R. K. Shields, Y. Toyoda, E. J. Kwak et al., Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity, Antimicrobial Agents and Chemotherapy, vol.56, issue.5, pp.2371-2377, 2012.
DOI : 10.1128/AAC.05219-11

J. Smith, N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani et al., Voriconazole Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, vol.50, issue.4, pp.1570-1572, 2006.
DOI : 10.1128/AAC.50.4.1570-1572.2006

A. Imhof, D. J. Schaer, U. Schanz, and U. Schwartz, 110 Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring, International Journal of Infectious Diseases, vol.10, pp.739-742, 2006.
DOI : 10.1016/S1201-9712(06)80107-4

D. W. Denning, P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht et al., Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis, Clinical Infectious Diseases, vol.34, issue.5, pp.563-571, 2002.
DOI : 10.1086/324620

W. B. Park, N. H. Kim, K. H. Kim, S. H. Lee, W. S. Nam et al., The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial, Clinical Infectious Diseases, vol.55, issue.8, pp.55-1080, 2012.
DOI : 10.1093/cid/cis599

R. Hyland, B. C. Jones, and D. A. Smith, Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole, Drug Metabolism and Disposition, vol.31, issue.5, pp.31-540, 2003.
DOI : 10.1124/dmd.31.5.540

Z. Desta, X. Zhao, J. G. Shin, and D. A. Flockhart, Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism, Clinical Pharmacokinetics, vol.32, issue.4, pp.41-913, 2002.
DOI : 10.2165/00003088-200241120-00002

A. Li-wan-po, T. Girard, P. Farndon, C. Cooley, and J. Lithgow, Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17, British Journal of Clinical Pharmacology, vol.29, issue.3, pp.222-230, 2010.
DOI : 10.1111/j.1365-2125.2009.03578.x

G. Mikus, V. Schöwel, M. Drzewinska, J. Rengelshausen, R. Ding et al., Potent cytochrome P450 2C19 genotype???related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir, Clinical Pharmacology & Therapeutics, vol.80, issue.2, pp.126-135, 2006.
DOI : 10.1016/j.clpt.2006.04.004

M. C. Verdier, D. Bentué-ferrer, O. Tribut, and E. Bellissant, Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma, Clinical Chemistry and Laboratory Medicine, vol.48, issue.10, pp.1515-1522, 2010.
DOI : 10.1515/CCLM.2010.252

K. Matsumoto, K. Ikawa, K. Abematsu, N. Fukunaga, K. Nishida et al., Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes, International Journal of Antimicrobial Agents, vol.34, issue.1, pp.91-94, 2009.
DOI : 10.1016/j.ijantimicag.2009.01.008

S. H. Kim, D. S. Yim, S. M. Choi, J. C. Kwon, S. Han et al., Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients, International Journal of Infectious Diseases, vol.15, issue.11, pp.15-753, 2011.
DOI : 10.1016/j.ijid.2011.06.004

A. Pascual, T. Calandra, S. Bolay, S. Bolay, J. Bille et al., Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, vol.46, issue.2, pp.201-211, 2008.
DOI : 10.1086/524669

A. E. Boyd, S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil et al., Adverse Reactions to Voriconazole, Clinical Infectious Diseases, vol.39, issue.8, pp.1241-1244, 2004.
DOI : 10.1086/424662
URL : http://cid.oxfordjournals.org/cgi/content/short/39/8/1241

S. Weiler, H. Zoller, I. Graziadei, W. Vogel, R. Bellmann-weiler et al., Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis, Antimicrobial Agents and Chemotherapy, vol.51, issue.9, pp.3459-3460, 2007.
DOI : 10.1128/AAC.00791-07

H. Rozé, M. Lafargue, O. Joannes-boyau, H. Batoz, C. Dromer et al., Toxicokinetics of voriconazole during massive intentional poisoning, Journal of Antimicrobial Chemotherapy, vol.64, issue.3, pp.662-663, 2009.
DOI : 10.1093/jac/dkp219

N. Wood, K. Tan, L. Purkins, G. Layton, J. Hamlin et al., Effect of omeprazole on the steady-state pharmacokinetics of voriconazole, British Journal of Clinical Pharmacology, vol.46, issue.Suppl. 2, pp.56-61, 2003.
DOI : 10.1046/j.1365-2125.2003.02000.x

L. Jeu, F. J. Piacenti, A. G. Lyakhovetskiy, and H. B. Fung, Voriconazole, Clinical Therapeutics, vol.25, issue.5, pp.1321-1381, 2003.
DOI : 10.1016/S0149-2918(03)80126-1